Alawad Mouhammad J, Albuni Mhd Kutaiba, Subahi Eihab A, Kamal Ijaz
Internal Medicine Residency Program, Medical Education, Hamad Medical Corporation, Doha, QAT.
Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Cureus. 2021 Oct 19;13(10):e18904. doi: 10.7759/cureus.18904. eCollection 2021 Oct.
Rifampicin is an established and effective antibiotic and a gold standard in treating tuberculosis (TB). Venous thromboembolism (VTE) events are a rare side effect of rifampicin, which has been reported in a few case reports. The exact mechanism is yet not clear, however, could include immunological and hematological causes. Here, we report a 56-year-old male who presented with pulmonary embolism (PE) three weeks after initiating rifampicin for latent TB management. Comprehensive investigations were done to rule out any other causes of thrombosis, especially malignancy, however, all tests were negative. The patient was treated with anticoagulant agents and rifampicin was switched to isoniazid after rifampicin discontinuation. He remained stable upon discharge and follow-up.
利福平是一种公认的有效抗生素，也是治疗结核病（TB）的金标准。静脉血栓栓塞（VTE）事件是利福平罕见的副作用，已有少数病例报告。确切机制尚不清楚，但可能包括免疫和血液学原因。在此，我们报告一名56岁男性，在开始使用利福平治疗潜伏性结核病三周后出现肺栓塞（PE）。进行了全面检查以排除任何其他血栓形成原因，尤其是恶性肿瘤，但所有检查均为阴性。患者接受了抗凝剂治疗，停用利福平后改用异烟肼。出院及随访时他情况稳定。
